Esmolol versus diltiazem in the treatment of postoperative atrial fibrillation/atrial flutter after open heart surgery.
BACKGROUND
Supraventricular tachyarrhythmias are common after open heart surgery. Possible causative factors for these arrhythmias include operative trauma, atrial ischemia, electrolyte imbalances, pericardial irritation, and excess catecholamines. Two agents commonly used to control ventricular rate in atrial fibrillation or atrial flutter (AF/AFL) are beta-blockers and calcium channel blockers.


RESULTS
This randomized study was designed to compare the safety and efficacy of intravenous diltiazem versus intravenous esmolol in patients with postoperative AF/AFL after coronary bypass surgery and/or valve replacement surgery. A comparative cost analysis was also performed. Thirty patients received either esmolol (n = 15) or diltiazem (n = 15) for AF/AFL. During the first 6 hours of treatment, 66.6% of esmolol-treated patients converted to sinus rhythm compared with 13.3% of the diltiazem-treated patients (P <.05). At 24 hours, 66.6% of the diltiazem group converted to SR compared with 80% of the esmolol group (not significant). Drug-induced side effects, time to rate control (<90 beats/min), number of patients requiring cardioversion, and length of hospitalization were similar for the two groups. The drug cost/successfully treated patient for esmolol versus diltiazem was $254 versus $437 at 6 hours and $529 versus $262 at 24 hours.


CONCLUSIONS
Although this is a small study, it suggests that esmolol is more effective in converting patients to normal sinus rhythm than diltiazem during the initial dosing period. No differences in conversion rates were observed between the two groups after 24 hours. Additional studies are needed to confirm whether esmolol is the initial drug of choice in patients with postoperative AF/AFL after coronary bypass surgery.
Mooss
A N
AN
Creighton University Medical Center, Omaha, NE, USA.
Wurdeman
R L
RL
Mohiuddin
S M
SM
Reyes
A P
AP
Sugimoto
J T
JT
Scott
W
W
Hilleman
D E
DE
Seyedroudbari
A
A
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D001282:Atrial Flutter / Q000188:drug therapy* / Q000209:etiology; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D004110:Diltiazem / Q000008:administration & dosage* / Q000191:economics; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy; D011336:Probability; D011379:Prognosis; D011412:Propanolamines / Q000008:administration & dosage* / Q000191:economics; D012016:Reference Values; D015996:Survival Rate; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D004110:Diltiazem; C036604:esmolol